SHP2
46 programs · 45 companies
Programs
46
Companies
45
Active Trials
23
Targeting SHP2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | CeliacRA | |
| MRK-1380 | Merck & Co | Preclinical | Prostate Ca | |
| ABB-1817 | AbbVie | Phase 3 | MMDravet | |
| AZN-8281 | AstraZeneca | Phase 1 | GARSV | |
| AZN-8478 | AstraZeneca | NDA/BLA | FabryParkinson's | |
| MRN-7409 | Moderna | NDA/BLA | MCCPV | |
| 180-3597 | Innovent Bio | Preclinical | Ewing SarcomaLGS | |
| Tezelucimab | Ascendis Pharma | Preclinical | SMA | |
| Surarasimod | Xenon Pharma | Phase 2 | Endometrial CaFSGS | |
| SLR-4773 | Acelyrin | Preclinical | NarcolepsyFSGS | |
| Zoriosocimab | Schrodinger | Approved | UCSMA | |
| GRF-4589 | Grifols | Phase 2 | GISTDMD | |
| UCB-6099 | UCB | Approved | AngelmanFabry | |
| TLX-9196 | Telix Pharma | Phase 1/2 | CSUCeliac | |
| MEM-IIT-677 | Memorial Sloan Kettering | Preclinical | WM | |
| NAT-IIT-719 | Natl Cancer Ctr Japan | Preclinical | Obesity | |
| Semacilimab | Seagen (Pfizer) | Phase 3 | Pancreatic CaGIST | |
| Olpaglumide | Third Rock | Phase 2/3 | RCCAtopic Derm | |
| Tezevorutinib | TransCode Therapeutics | Approved | Angelman | |
| Tezezanubrutinib | Atossa Therapeutics | Preclinical | PNHFL | |
| Talatuximab | Vera Therapeutics | Phase 1/2 | FabryPAH | |
| LTR-8109 | Lantern Pharma | Phase 1 | T2DParkinson's | |
| Lisoderotide | Aerpio Pharmaceutics | Phase 3 | CLLFabry | |
| Tezesotorasib | Cartesian Therapeutics | Preclinical | LNCRC | |
| AVE-316 | Aveo Pharma (LG Chem) | Phase 3 | DLBCLBladder Ca | |
| Taladerotide | Zenas BioPharma | Phase 2/3 | CF | |
| SON-6232 | Sonnet Bio | Phase 2/3 | AMLUC | |
| Zorisertib | BioHaven (Pfizer) | Approved | RSVParkinson's | |
| Riluzasiran | Arcellx | Phase 2/3 | NSCLCEpilepsy | |
| Mavuinavolisib | Vaxcyte | NDA/BLA | PompeCrohn's | |
| AUR-7289 | Aurobindo | Preclinical | Pancreatic CaSchizophrenia | |
| KIA-7048 | Kiadis (Sanofi) | Phase 3 | UCADHD | |
| PLU-3424 | Plurilock | Phase 2 | CMLACC | |
| 417-3039 | OBI Pharma | Phase 2 | DLBCLFTD | |
| Sovafutibatinib | Grifols SA | Phase 1/2 | SCDALS | |
| MVI-4741 | Medivir | Phase 2 | UCCeliac | |
| ERY-9084 | Erytech Pharma | NDA/BLA | Ewing Sarcoma | |
| PRO-4197 | Probiomed | Approved | Wilms | |
| TAB-303 | Tabuk Pharma | Phase 3 | GBM | |
| RIK-IIT-299 | RIKEN | Preclinical | Bladder Ca | |
| WES-IIT-660 | West China Hosp | Phase 1 | Bladder Ca | |
| 002-8467 | Kelun Pharma | Phase 1/2 | Ewing SarcomaEpilepsy | |
| Tirainavolisib | Zhifei Biological | Approved | IPF | |
| A-1206 | Agilent Technologies | Phase 2/3 | DMDRSV | |
| Riluzumab | Zoetis | Approved | Hemophilia APsA | |
| ABB-7827 | Abbisko Therapeutics | NDA/BLA | MDS |